Long-Term Data Show Improved CR Rates for Cosibelimab in Advanced CSCC

Long-term data demonstrated that treatment with cosibelimab improved complete response rates over time in patients with locally advanced or metastatic cutaneous squamous cell carcinoma in a phase 1 trial.

Related Keywords

,Checkpoint Therapeutics Inc ,Checkpoint Therapeutics ,Prescription Drug User Fee Act ,Cosibelimab ,Patients With Locally Advanced Or Metastatic Cutaneous Squamous Cell Carcinoma ,Nct03212404 ,James Oliviero ,